|
|
|
|
|||||
|
|
|
New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 17, Summit Therapeutics Inc. (NASDAQ:SMMT) announced the expansion of its Phase 3 clinical development program called HARMONi-GI3, for its candidate Ivonescimab.
Ivonescimab is a novel biospecific antibody that combines with chemotherapy in patients with unresectable metastatic colorectal cancer. The phase 3 trials will compare ivonescimab plus chemotherapy with bevacizumab plus chemotherapy as first-line therapy for patients with CRC. Management noted that the trial is global and they aim to enroll around 600 patients. Trial sites in the United States are expected to start soon.
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biotechnology company that is focused on developing therapies mainly for cancer treatment.
While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| 5 hours | |
| 9 hours | |
| 13 hours | |
| Oct-20 | |
| Oct-20 | |
| Oct-20 | |
| Oct-19 | |
| Oct-19 | |
| Oct-17 | |
| Oct-15 | |
| Oct-08 | |
| Oct-07 | |
| Oct-05 | |
| Oct-02 | |
| Oct-01 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite